September 10, 2025 a 08:00 am
LLY: Fundamental Ratio Analysis - Eli Lilly and Company
Eli Lilly and Company has a strong foothold in the pharmaceutical industry with a diversified product lineup addressing diabetes, cancer, and other critical health conditions. The stock is driven by innovative research and strategic collaborations, promising potential for long-term growth. However, investors should be cautious of the inherent risks associated with the healthcare sector.
Fundamental Rating
Eli Lilly shows a solid fundamentals rating, signifying its robust financial metrics. Below are the core evaluation categories alongside their corresponding scores and a visual score bar.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 1 | |
| Price to Earnings | 1 | |
| Price to Book | 1 |
Historical Rating
The historical data shows consistency in performance with room for growth over time. Below is a comparison of the current and past scores.
| Date | Overall Score | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-09-09 | 3 | 4 | 5 | 5 | 1 | 1 | 1 |
| Previous Date | 0 | 4 | 5 | 5 | 1 | 1 | 1 |
Analyst Price Targets
Analyst price targets reflect optimism for Eli Lilly's stock with considerable room for growth.
| High | Low | Median | Consensus |
|---|---|---|---|
| $1050 | $700 | $715 | $798 |
Analyst Sentiment
Analysts generally have a favorable outlook on Eli Lilly, categorizing it as a "Buy".
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 32 | |
| Hold | 8 | |
| Sell | 2 | |
| Strong Sell | 0 |
Conclusion
Eli Lilly and Company showcases strong potential backed by innovative research and strategic collaborations in the pharmaceutical industry. While their high analyst confidence and solid rating profiles point to expansive growth opportunities, the healthcare sector's inherent uncertainties and competition always pose risks. Investors may find Eli Lilly to be an attractive buy for long-term gain but should remain cautious of market volatility and industry-specific risks.